KISKALI
(Ribociclib)
(200 mg)
(63)
(Таб)
KISQALI (ribociclib) 200 mg 63 caps, Novartis mfd
In Stock
Indications for use in combination with an aromatase inhibitor and fulvestrant for the treatment of women with locally enlarged or metastatic breast cancer with a positive HR (hormone receptor) status and a negative HER2 (human epidermal growth factor receptor) status Type 2) for cobalt endocrine therapy or for the treatment of women , which were previously discontinued endocrine therapy.
In premenopausal or perimenopausal women, endocrine therapy is carried out in combination with a luteinizing hormone releasing hormone (LHRH) agonist.
-
Commercial name:KISKALI
-
Сhemical name:Ribociclib
-
Dosage:200 mg
-
Quantity:63
-
Release form:Таб
-
Производитель:NOVARTIS Швейцарія
Ніде не міг знайти цей препарат за адекватну ціну ! Дякую